In the context of colorectal cancer treatment, recent studies suggest that combining AuNPs with the chemotherapy drug doxorubicin and an anti-PD-L1 antibody—an immune checkpoint inhibitor that blocks the PD-L1 protein to help the immune system attack cancer cells—can lead to more effective treatment outcomes. Here, CD274 is linked to colorectal cancer.